Investing.com - Bio Path reported on Tuesday third quarter earnings that missed analysts' forecasts and revenue that was in line with expectations.
Bio Path announced earnings per share of $-0.490 on revenue of $0.00. Analysts polled by Investing.com anticipated EPS of $-0.460 on revenue of $0.
Bio Path shares are down 59% from the beginning of the year, still down 71.02% from its 52 week high of $5.28 set on November 29, 2021.
Bio Path shares lost 3.77% in intra-day trade following the report.
Bio Path follows other major Healthcare sector earnings this month
Bio Path's report follows an earnings beat by J&J on October 18, who reported EPS of $2.55 on revenue of $23.79B, compared to forecasts EPS of $2.48 on revenue of $23.36B.
Eli Lilly had beat expectations on November 1 with third quarter EPS of $1.98 on revenue of $6.94B, compared to forecast for EPS of $1.91 on revenue of $6.91B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar